Investigating factors that lead to antibody formation after blood transfusions
Donor and unit factors associated with recipient RBC alloimmunization formation
This study is looking at how different traits of blood donors and the blood they give can affect the chances of patients, especially those with sickle cell disease and thalassemia, developing antibodies after receiving blood transfusions, with the hope of making transfusions safer and improving health outcomes for these patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10670887 on NIH RePORTER |
What this research studies
This research examines how certain characteristics of blood donors and blood units contribute to the formation of antibodies in patients receiving red blood cell transfusions. By analyzing a large dataset that includes health information from various hospitals, the study aims to identify patterns and factors that increase the risk of alloimmunization, particularly in patients with conditions like sickle cell disease and thalassemia. The goal is to improve transfusion safety and patient outcomes by understanding these associations better.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with sickle cell disease, thalassemia major, or other conditions that require regular blood transfusions.
Not a fit: Patients who do not require blood transfusions or have conditions unrelated to alloimmunization may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer blood transfusions and reduced complications for patients with conditions requiring frequent transfusions.
How similar studies have performed: Previous research has shown that understanding donor and unit factors can significantly impact transfusion outcomes, suggesting that this approach has the potential for meaningful advancements.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Hauser, Ronald G. — Yale University
- Study coordinator: Hauser, Ronald G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.